Aim: To compare the clinical and radiographic efficacy of Biodentine , ProRoot ® White Mineral Trioxide Aggregate (WMTA) and Tempophore as pulpotomy medicaments in the treatment of carious primary molars. Methodology: A parallel-design, randomized controlled trial was developed. Patients above 3 years of age with carious primary teeth with vital pulps without spontaneous pain or history of swelling were included. Fifty-eight patients (82 teeth) with a mean age of 4.79 ± 1.23 years were included. The teeth were randomized, blinded and allocated to one of the three groups (Biodentine , ProRoot ® WMTA or Tempophore ) for pulpotomy treatment. All teeth were followed up clinically and radiographically (after 6, 12 and 18 months) by two blinded calibrated investigators. A generalized estimating equation (GEE), Wald chi-square test and an intention-to-treat analysis (ITT) with ‘last carried forward’ approach were performed using Statistical Package for Social Sciences v 21.0 (IBM Corp., Armonk, NK, USA). Results: Forty-six patients and 69 teeth were available for follow-up after 18 months. Clinical success (radiographic success in parenthesis) was 95.24% (94.4%), 100% (90.9%) and 95.65% (82.4%) in the Biodentine , ProRoot ® WMTA and Tempophore groups, respectively, but the difference was not significant. Pulp canal obliteration was significantly different amongst the experimental groups as the Biodentine group exhibited significantly more pulp canal obliteration when compared to the ProRoot ® WMTA group at 6 months (P = 0.008) and 18 months (P = 0.003). Conclusions: After 18-month follow-up, there was no significant difference between Biodentine in comparison with ProRoot ® WMTA or Tempophore .

Original languageEnglish
Pages (from-to)215-228
Number of pages14
JournalInternational Endodontic Journal
Issue number3
Publication statusPublished - Mar 2017

    Research areas

  • Biodentine, mineral trioxide aggregate, pulp therapy, pulpotomy, Tempophore

ID: 21019364